mRNA Vaccine Continues to Show Promise in Resected Melanoma
Source: Onc Nursing News, October 2023
The individualized neoantigen therapy mRNA-4157 (V940), combined with pembrolizumab (Keytruda), improved relapse-free survival (RFS) and distant metastasis-free survival (DMFS) compared with pembrolizumab alone in patients with high-risk resected melanoma, according to findings from the phase 2 KEYNOTE-942 trial (NCT03897881) presented at the 2023 European Society for Medical Oncology Congress (ESMO).
Patients treated with mRNA-4157 plus pembrolizumab experienced an approximately 44% reduction in the risk of death or recurrence with respect to RFS compared with those receiving pembrolizumab alone (HR, 0.561; 95% CI, 0.309-1.017; P = .0266). Additionally, the RFS rates in the combination and monotherapy arms, respectively, were 83.4% vs 77.1% at 12 months and 78.6% vs 62.2% at 18 months.
The individualized neoantigen therapy in combination with pembrolizumab also improved DMFS compared with pembrolizumab monotherapy (HR, 0.347; 95% CI, 0.145-0.828; P = .0063). The 18-month DMFS rate was 91.8% in the mRNA-4147 plus pembrolizumab arm and 76.8% in the single-agent pembrolizumab arm.